Regdanvimab

Biorbyt

Regdanvimab

10

Research Use Only

Monoclonal

Unconjugated

98.00%

Regdanvimab (CT-P59) is a human monoclonal antibody targeting the receptor-binding domain of the SARS-CoV-2 spike protein, inhibiting the viruss cell entry by blocking its interaction with the ACE2 receptor. It is utilized in COVID-19 research [1].

-20°C,2°C to 8°C

12352203